Serum survivin increases in prolactinoma

Basit Öğe Kaydı
dc.authorid0000-0001-5472-7465en_US
dc.contributor.authorDellal, Fatma Dilek
dc.contributor.authorNiyazoğlu, Mutlu
dc.contributor.authorGorar, Süheyla
dc.contributor.authorAdemoğlu, Esranur
dc.contributor.authorCandan, Zehra
dc.contributor.authorBekdemir, Handan
dc.contributor.authorHacıoğlu, Yalçın
dc.contributor.authorKaya, Fatih Öner
dc.date.accessioned2024-07-12T21:04:29Z
dc.date.available2024-07-12T21:04:29Z
dc.date.issued2015en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractBackground Prolactinoma is the most common adult pituitary adenoma. Survivin is a member of the family of inhibitors of apoptosis proteins. Its expression is observed in many tumors. Survivin expression has shown in prolactinoma tissue before but no study exists showing serum survivin level. The aim of the present study was to investigate serum survivin levels in patients with prolactinoma and demonstrate its value in diagnosis of the disease. Methods The group of patients consisted of 25 women, aged from 17 to 51 years. As a control group, 21 healthy women, aged from 22 to 45 years were included. Twenty patients had microprolactinoma, while five patients had macroprolactinoma. All patients had received dopamine agonist treatment. Serum survivin levels were measured in all of the groups. Results Survivin levels were significantly higher in prolactinoma patients compared to controls (19.04 (10 - 38) pg/mL; 15.05 (8 - 22) pg/mL; P = 0.042). There was no difference between microadenoma and macroadenoma patients in survivin levels (19.22 (10 - 38) pg/mL; 18.40 (16 - 22) pg/mL; P = 0.914). In correlation analysis, survivin was not correlated with other parameters. Conclusions We consider that higher survivin levels might be a molecular marker predicting the presence of prolactinoma and may be useful for the diagnosis. But large-scale research is needed to clarify its role in diagnosis of prolactinoma patients.en_US
dc.identifier.citationDellal, F.D., Niyazoğlu, M., Gorar, S. vd. (2015). Serum survivin increases in prolactinoma. J Clin Med Res., Pubmed. 7(4), s. 248-252.en_US
dc.identifier.endpage252en_US
dc.identifier.issue4en_US
dc.identifier.startpage248en_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330017/
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3787
dc.identifier.volume7en_US
dc.institutionauthorKaya, Fatih Öner
dc.language.isoenen_US
dc.publisherPubmeden_US
dc.relation.ispartofJ Clin Med Resen_US
dc.relation.isversionof10.14740/jocmr2098wen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY01763
dc.subjectSurvivinen_US
dc.subjectProlactinomaen_US
dc.subjectMicroprolactinomaen_US
dc.subjectMacroprolactinomaen_US
dc.subjectPituitary neoplasmsen_US
dc.titleSerum survivin increases in prolactinomaen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu